PCH
CLDX icon

Polar Capital Holdings’s Celldex Therapeutics CLDX Stock Holding History

Polar Capital Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,008,163
Closed -$27.4M – 249
2025
Q4 		$27.4M Sell
1,008,163
-292,273
-22% -$7.7M 0.11% 136
2025
Q3 		$33.6M Buy
1,300,436
+72,001
+6% +$1.67M 0.16% 110
2025
Q2 		$25M Sell
1,228,435
-175,000
-12% -$3.41M 0.13% 125
2025
Q1 		$25.5M Sell
1,403,435
-162,396
-10% -$3.63M 0.16% 132
2024
Q4 		$39.6M Sell
1,565,831
-1,155,046
-42% -$31.4M 0.22% 112
2024
Q3 		$92.5M Sell
2,720,877
-355,906
-12% -$13.6M 0.44% 51
2024
Q2 		$114M Buy
3,076,783
+17,291
+0.6% +$652K 0.67% 38
2024
Q1 		$128M Sell
3,059,492
-76,379
-2% -$3.14M 0.67% 33
2023
Q4 		$124M Buy
3,135,871
+709,115
+29% +$20.9M 0.76% 29
2023
Q3 		$66.8M Buy
2,426,756
+10,000
+0.4% +$313K 0.49% 57
2023
Q2 		$82M Buy
2,416,756
+148,767
+7% +$5.01M 0.41% 60
2023
Q1 		$81.6M Buy
2,267,989
+717,989
+46% +$31M 0.53% 54
2022
Q4 		$69.1M Buy
1,550,000
+101,066
+7% +$3.61M 0.55% 57
2022
Q3 		$40.7K Buy
1,448,934
+801,514
+124% +$24.6M 0.26% 89
2022
Q2 		$17.5K Sell
647,420
-602,580
-48% -$17.5M 0.1% 155
2022
Q1 		$42.6K Buy
1,250,000
+250,000
+25% +$7.99M 0.19% 102
2021
Q4 		$38.6K Buy
1,000,000
+277,157
+38% +$12.1M 0.15% 116
2021
Q3 		$39K Buy
722,843
+222,843
+45% +$10.5M 0.16% 115
2021
Q2 		$16.7K Hold
500,000
– – 0.07% 186
2021
Q1 		$10.3M Sell
500,000
-500,000
-50% -$11.5M 0.06% 204
2020
Q4 		$17.5M Buy
+1,000,000
New +$18M 0.11% 172

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Polar Capital Holdings's CLDX Position: Q1 2026 in Review

Polar Capital Holdings sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 1,008,163 shares — an estimated $27.4M sold.

Polar Capital Holdings first reported a position in CLDX in Q4 2020 and held it in 21 quarters. The position peaked at $128M in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Polar Capital Holdings reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Polar Capital Holdings sold 1,008,163 Celldex Therapeutics shares in Q1 2026, an estimated $27.4M.
  • Polar Capital Holdings first reported a position in Celldex Therapeutics in Q4 2020 and held it in 21 quarters.
  • Polar Capital Holdings's Celldex Therapeutics position peaked at $128M in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.